All In Biotech

Drug Trial Radar · NCT06311578

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Nov 8, 2028

Study completion Feb 14, 2033

Sponsor

Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.

Conditions

  • Neoplasms

Interventions

  • JNJ-87704916Drug

    JNJ-87704916 will be administered as an intratumoral injection.

  • CetrelimabDrug

    Cetrelimab will be administered.

  • Standard of Care PD(L)-1Drug

    Frontline anti-PD(L)-1 antibody therapy will be administered as standard of care treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: Up to 5 years
  2. Number of Participants with Adverse Events (AEs) by SeverityTime frame: From first dose up to 100 days after last dose of study treatment (up to 5 years)

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Suspended

  • UPMC Cancer Centers

    Pittsburgh, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Hosp Univ Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hosp Univ Hm Sanchinarro

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.